Alnylam Pharmaceuticals (ALNY) PT Raised to $265 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals (ALNY) PT Raised to $225 at Morgan Stanley
August 3, 2022 12:57 PM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $225.00 (from $159.00) while maintaining a Equalweight rating.... More
Alnylam Pharma (ALNY) Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint
August 3, 2022 7:01 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months... More
Alnylam Pharma (ALNY) Halted, news Pending
August 3, 2022 6:58 AM EDTAlnylam Pharma (NASDAQ: ALNY) Halted, news Pending
... More